News | News By Subject | News by Disease News By Date | Search News

Angioedema News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Biocryst (BCRX) Stock Caught Fire After Reporting Positive Phase II HAE Data     5/26/2017
Shire (SHPG)'s $6.5 Billion Dyax (DYAX) Bet Pays Off as Lanadelumab Wows in Phase III Study     5/18/2017
Stock Plunges as Biocryst (BCRX)'s Angioedema Drug Flunks Phase II Study     2/8/2016
FDA Bestows Breakthrough Therapy Designation on Dyax Corp. (DYAX)'s HAE Drug As Suitors Circle     7/7/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Pharming Group (PHGUF.PK), Salix (SLXP) Wins FDA Approval For Ruconest®     7/17/2014
Pharming Group (PHGUF.PK)-Santarus Inc. (SNTS) Ruconest Phase III Study Meets Primary Endpoint     11/7/2012
FDA Lifts Temporary Hold on ViroPharma Incorporated (VPHM) Treatment     9/21/2012
FDA Approves Shire plc's Firazyr to Treat Acute Attacks of Hereditary Angioedema     8/25/2011
Pharming Group (PHGUF.PK) Discontinues Funding of DNage     1/31/2011
Shire plc: FIRAZYR FAST-3 Phase 3 Study Endpoints Statistically Significant Results for Hereditary Angioedema     12/1/2010
Dyax Corp. (DYAX), CMIC Co., Ltd. to Develop, Market Angioedema Drug; Dyax to Receive $4 Million Upfront and Eligible for $102 Million More in Milestone Payments     9/30/2010
Data from Dyax Corp. (DYAX)'s First Phase 3 Trial (EDEMA3(R)) for KALBITOR(R) (ecallantide) Published in The New England Journal of Medicine     8/5/2010

News from Around the Web

Press Releases
Biocryst (BCRX) Announces Initiation Of ZENITH-1, A Clinical Trial To Evaluate BCX7353 As An Acute Treatment Of Hereditary Angioedema Attacks     8/2/2017
CSL Behring Release: HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available In The United States For Patients With Hereditary Angioedema     7/25/2017
CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human])     7/21/2017
CSL Behring Release: FDA Approves HAEGARDA (C1 Esterase Inhibitor Subcutaneous [Human]), First And Only Subcutaneous Preventive Treatment For Hereditary Angioedema     6/26/2017
Attune Announces Positive Data From Recent Pre-Clinical Studies For ATN-249, An Oral Plasma Kallikrein Inhibitor For The Treatment Of HAE At C1-INH Deficiency Workshop     5/22/2017
Biocryst (BCRX) Expands Development Of BCX7353 To Explore Treatment Of Acute HAE Attacks     4/12/2017
Shire (SHPG) Receives European Approval For Label Extension Of CINRYZE (C1 Inhibitor [Human]) To Prevent And Treat Hereditary Angioedema (HAE) Attacks In Paediatric Patients With HAE     3/16/2017
Attune Announces Pre-Clinical Data For ATN-249, An Oral Plasma Kallikrein Inhibitor For The Treatment Of HAE At AAAAI     3/6/2017
Attune Announces Late-Breaking Poster Presentation Of ATN-249, An Oral Kallikrein Inhibitor For The Treatment Of HAE     3/1/2017
Biocryst (BCRX) Reports Positive Interim Results From Its APeX-1 Trial     2/27/2017
The New England Journal of Medicine Publishes Phase Ib Results For Shire (SHPG)'s Investigational Treatment For Hereditary Angioedema, A Rare Genetic Disease     2/23/2017
FDA Accepts CSL Behring's Biologics License Application For First Subcutaneous Prophylactic Therapy To Prevent Hereditary Angioedema Attacks     8/30/2016
KalVista Pharmaceuticals Announces Initiation Of A Phase 1 Clinical Trial Of KVD818 For The Treatment Of Hereditary Angioedema     8/11/2016
Biocryst (BCRX) Announces Initiation Of The Apex-1 Clinical Trial Of BCX7353 For Hereditary Angioedema     8/11/2016
U.S. FDA Approves CSL Behring's Berinert As The First And Only Pediatric Treatment For Hereditary Angioedema (HAE)     7/18/2016